Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01974258
Title Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients
Recruitment Withdrawn
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Hoffmann-La Roche
Indications

lung non-small cell carcinoma

melanoma

Advanced Solid Tumor

colorectal cancer

Therapies

Onartuzumab + Vemurafenib

Cobimetinib + Onartuzumab

Cobimetinib + Onartuzumab + Vemurafenib

Age Groups: adult | senior
Covered Countries USA

Additional content available in CKB BOOST